AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Cyclin-dependent kinase 10

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q15131

UPID:

CDK10_HUMAN

Alternative names:

Cell division protein kinase 10; Serine/threonine-protein kinase PISSLRE

Alternative UPACC:

Q15131; A8K370; A8K8I6; A8MXU6; B3KQJ3; B7Z420; D3DX82; D3DX83; Q0VGZ7; Q15130; Q6PJC0

Background:

Cyclin-dependent kinase 10 (CDK10), also known as Serine/threonine-protein kinase PISSLRE, plays a pivotal role in cell division and the regulation of the actin cytoskeleton. It is known for phosphorylating the transcription factor ETS2, which influences its degradation, and for its involvement in actin dynamics through the phosphorylation of PKN2. CDK10's activity is crucial for the negative regulation of ciliogenesis, promoting RhoA signaling.

Therapeutic significance:

CDK10 is linked to Al Kaissi syndrome, a disorder marked by growth retardation, spine malformation, and developmental delays, due to gene variants affecting CDK10. Understanding the role of CDK10 could open doors to potential therapeutic strategies for this syndrome.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.